Moderna earlier that day released a new analysis from its Phase 3 study: Data showed that between December 2020 and March 2021, there were 88 confirmed breakthrough cases (0.77%) among the 11,431 vaccinated people (0.77%), while between July and October 2020, there were 162 breakthrough cases (1.10%) among the 14,746 trial participants vaccinated. The
report analysis stated that among a group of trial participants who had recently received the vaccine, the incidence of breakthrough cases was lower. But at the same time, it is also necessary to admit that the protectiveness of the new crown vaccine is weakening over time.
Hogg said that the breakthrough cases cannot be attributed to Delta. Breakthrough cases among vaccinated people are the result of the dual effects of "vaccine protection, weakening over time" and "highly contagious variants". The Delta variant is not an immune escape variant. This variant only weakens our defense when it is protected by the vaccine.
Hogg said this latest result provides a reason for the widespread use of reinforcement needles, but the report has not been peer-reviewed. At present, the scientific community has disagreements over whether it is necessary to inject reinforcement needles into the general public.
The FDA Vaccine Advisory Committee of the U.S. Food and Drug Administration will hold a meeting today to discuss with an external expert group whether there is enough data to support the widespread promotion of enhanced injections across the United States. The Biden administration has said it hopes to start providing reinforcement needles to the public as early as next week, but it depends on whether the FDA authorizes it.
Canada officially approved the name change of three vaccines, Pfizer-BioNTech (Pfizer) was renamed "Comirnaty" , pronounced co-MER-na-tee, and the Chinese name is Fubitai. The term (Comirnaty) is composed of the words "the official name of novel coronavirus pneumonia, COVID-19 (Co), messenger ribonucleic acid mRNA (mirna), population community and immunity (ty).
Moderna vaccine (Modna) is renamed "SpikeVax" , and there is currently no unified Chinese name.
AstraZeneca vaccine (AstraZeneca) is renamed "Vaxzevria" , and there is currently no unified Chinese name. The three vaccines of
are just "changes of names", and there is no change in the vaccine itself. Currently, the EU and the United States have begun to use these new names.
